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KEYWORDS	
	 A	reversed	phase	high	performance	liquid	chromatographic	method	for	the	determination	of
process	related	impurities	in	pioglitazone	hydrochloride	was	developed	and	validated.	High‐
quality	 separation	 was	 achieved	 on	 a	 Luna	 C18	 column	 (150	 mm	 ×	 4.6	 mm,	 3	 µm)	 using
gradient	elution	at	a	flow	rate	of	1	mL/min	and	a	column	temperature	of	45	°C.	UV	detection
was	 performed	 at	 254	 nm.	 The	 validation	 was	 performed	 according	 to	 the	 International
Conference	on	Harmonization	(ICH)	guidelines.	In	addition,	the	solution	stability	and	method
robustness	 were	 examined.	 The	 method	 gives	 satisfactory	 separation	 of	 impurities	 of
pioglitazone	 hydrochloride	 and	 so	 it	 is	 suitable	 for	 quantification	 of	 the	 process	 related
impurities	as	well	as	for	the	assay	of	the	active	compound.	
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1.	Introduction	
	
Pioglitazone	 hydrochloride	 is	 an	 oral	 anti	 diabetic	 agent	
that	 acts	 primarily	 by	 decreasing	 insulin	 resistance.	
Pioglitazone	hydrochloride	is	used	in	the	management	of	type	2	
diabetes	 mellitus	 (also	 known	 as	 non‐insulin‐dependent	
diabetes	 mellitus	 [NIDDM]	 or	 adult‐onset	 diabetes).	
Pioglitazone	 hydrochloride	 selectively	 stimulates	 nuclear	
receptor	 peroxisone	 proliferator‐activated	 receptor	 gamma	
(PPAR‐gamma).	Activation	of	PPAR	gamma	receptors	regulates	
the	 transcription	 of	 insulin‐responsive	 genes	 involved	 in	 the	
control	 of	 glucose	 production,	 transport	 and	 utilization.	
Pioglitazone	 Hydrochloride,	 a	 member	 of	 the	 drug	 group	
known	as	the	thiazolidinediones	or	"insulin	sensitizers",	 is	not	
chemically	 or	 functionally	 related	 to	 the	 alpha‐glucosidase	
inhibitors,	 the	 biguanides,	 or	 the	 sulfonylureas.	 Pioglitazone	
hydrochloride	stimulates	the	uptake	of	glucose	and	fatty	acids	
into	cells	by	promoting	the	synthesis	and	expression	of	cellular	
glucose	 and	 fatty	 acid	 transporters	 [1].	 Many	 studies	 of	
pioglitazone	 demonstrated	 the	 improvement	 of	 glycemic	
control,	HbA1c,	 fasting	plasma	glucose	 levels,	 and	serum	 lipid	
profiles	 [2,3].	 Pioglitazone	hydrochloride	undergoes	 extensive	
hepatic	metabolism,	predominantly	via	cytochrome	P450	(CYP)	
2C8	system.	Its	elimination	half‐life	was	3‐7	h.	Pioglitazone	and	
its	 metabolites	 were	 excreted	 via	 urine	 (15‐30%).	 The	
remainders	 were	 excreted	 into	 bile	 and	 feces	 [4‐6].	 More	
recently,	 pioglitazone	 and	 other	 active	 thiazolidinedione	 have	
been	 shown	 to	 bind	 to	 the	 outer	 mitochondrial	 membrane	
protein	 mitoNEET	 with	 affinity	 comparable	 to	 that	 of	
pioglitazone	 for	 PPARγ	 [7‐10].	 Pioglitazone	 hydrochloride	
reduces	 insulin	 resistance	 in	 the	 liver	 and	 peripheral	 tissues;	
increases	 the	expense	of	 insulin‐dependent	glucose;	decreases	
withdrawal	 of	 glucose	 from	 the	 liver;	 reduces	 quantity	 of	
glucose,	insulin	and	glycated	haemoglobin	in	the	bloodstream.	
Literature	survey	revealed	that	only	few	analytical	methods	
have	been	reported	for	determining	pioglitazone	hydrochloride	
in	dosage	forms	as	well	as	biological	fluids.	Zhong	and	Williams	
reported	 an	 analytical	 method	 for	 the	 simultaneous	
quantitation	 of	 pioglitazone	 and	 its	 metabolites	 in	 human	
serum	using	HPLC/UV	[11].	Yamashita	et	al.	have	developed	a	
HPLC	 method	 for	 determination	 of	 pioglitazone	 and	 its	
metabolites	 in	 human	 serum	 and	 urine.	 In	 this	 method	
separation	was	 achieved	 by	 inertsil	 ODS‐2	 column	 (150	×	4.6	
mm)	 with	 5	 µm	 particle	 size,	 mobile	 phase	 consists	 of	
phosphate	 buffer,	 methanol	 and	 acetonitrile;	 gradient	 elution	
was	performed	at	a	wavelength	269	nm	[12].	Radhakrishna	et	
al.	 reported	 determination	 of	 pioglitazone	 hydrochloride	 in	
bulk	 and	 pharmaceutical	 formulations	 by	 HPLC	 and	 MEKC	
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methods	using	C18	column	(250	×	4.6	mm)	5	µm	particle	size	
with	 a	 mobile	 phase	 consists	 of	 phosphate	 buffer	 and	
acetonitrile,	detection	was	carried	out	by	225	nm	[13].	Xue	et	
al.	have	studied	a	quantitative	determination	of	pioglitazone	in	
human	serum	by	direct‐injection	HPLC/MS	and	 its	application	
to	bioequivalence	study	[14].	Sane	et	al.	have	developed	a	HPLC	
method	 for	 simultaneous	 determination	 of	 pioglitazone	 and	
glimipride	[15].	Sripalakit	et	al.	have	reported	a	HPLC	method	
for	 the	 determination	 of	 pioglitazone	 in	 human	 plasma	 using	
UV	detection	and	its	application	to	a	pharmacokinetic	study.	In	
this	method	 chromatographic	 separation	was	 achieved	with	 a	
RP	 Apollo	 C18	 Column	 and	 mobile	 phase	 consisting	 of	
methanol,	 acetonitrile,	 phosphate	 buffer,	 at	 a	wavelength	 269	
nm	 [16].	 Lofty	 Saber	 reported	 a	HPLC	method	 for	 determina‐
tion	of	pioglitazone	hydrochloride	in	tablets	[17].	Tahmasebi	et	
al.	have	studied	an	extraction	of	trace	amounts	of	pioglitazone	
with	 hollow	 fiber	 liquid	 phase	 micro	 extraction	 by	 HPLC‐UV	
detection	in	biological	fluids	[18,19].	Although,	to	date	there	is	
no	 method	 reported	 for	 determination	 of	 process‐related	
substances	 of	 pioglitazone	 hydrochloride	 in	 the	 literature	
(Figure	 1).	 The	 present	 study	 is	 aimed	 at	 separation	 and	
determination	 of	 pioglitazone	 hydrochloride	 and	 its	 process‐
related	impurities	by	RP‐HPLC	method	[19‐21].		
	
	
	
Figure	 1.	 Chemical	 structures	 of	 the	 pioglitazone	 hydrochloride	 and	
impurities	A‐C.	
	
2.	Experimental	 	
	
2.1.	Instrumentation	
	
An	 integrated	 HPLC	 system	 with	 computer	 based	
chromatography	 software	 (empower)	 was	 used.	 The	 Water’s	
alliance	 system	 with	 2695	 quaternary	 low	 pressure	 gradient	
system,	auto	sampler,	column	thermostat	and	photodiode	array	
detector	was	used	for	this	experiment.		
	
2.2.	Chemicals	and	reagents	
	
Pioglitazone	 hydrochloride	 working	 standard	 and	 its	
process	 related	 impurities	 were	 synthesized	 at	 Pharmazell	
Research	 Centre,	 Visakhapatnam	 (India)	 and	 obtained	 as	 gift	
samples.	 HPLC	 grade	 acetonitrile	 was	 obtained	 from	 Merck.	
Analytical	grade	ammonium	acetate,	acetic	acid	was	used.	High	
purity	water	was	prepared	by	using	Milli‐Q	Elix	and	then	using	
Milli‐Q	 academic	 purification	 system	 (Millipore).	 5‐(4‐(2‐(5‐
Ethylpyridin‐2‐yl)ethoxy)benzyl)‐2‐iminothiazolidin‐4‐one	
was	purchased	from	(Sigma).	
2.3.	Preparation	of	solutions		
	
2.3.1.	Preparation	of	buffer	
	
1.54	g	of	ammonium	acetate	was	dissolved	 in	1000	mL	of	
water,	 pH	 was	 adjusted	 to	 4.6±0.05	 with	 acetic	 acid,	 filtered	
through	0.45	µ	size	 filter	paper	and	degassed	 in	 an	ultrasonic	
bath.	
	
2.3.2.	Preparation	of	mobile	phase	
	
Solvent	A:	A	mixture	of	acetonitrile	and	buffer	 in	the	ratio	
(43:57,	v:v)	was	prepared.	Solvent	B:	A	mixture	of	acetonitrile	
and	buffer	in	the	ratio	(80:20,	v:v)	was	prepared.	
	
2.3.3.	Preparation	of	diluent	
	
A	 mixture	 of	 tetrahydrofuran	 and	 methanol	 in	 the	 ratio	
(1:3,	v:v)	was	prepared.	
	
2.3.4.	Preparation	of	standard	solution	
	
Standard	solution	was	prepared	by	weighing	accurately	50	
mg	 of	 pioglitazone	 hydrochloride	 and	 transferred	 into	 50	mL	
volumetric	 flask	 containing	 30	 mL	 of	 diluent.	 The	 flask	 was	
then	sonicated	for	10	min	to	dissolve	the	drug	completely	and	
the	volume	made	up	to	50	mL	with	diluent	(1	mg/mL).	
	
2.3.5.	Preparation	of	test	solution	
	
About	 50	 mg	 of	 sample	 was	 weighed	 accurately	 and	
transferred	into	50	mL	volumetric	flask,	add	30	mL	of	diluent,	
sonicated	 for	 10	min	 to	 dissolve	 the	 drug	 completely	 and	 the	
volume	was	made	up	to	50	mL	with	diluent.	
	
2.3.6.	Preparation	of	impurity	mixture	
	
About	38	mg	of	pioglitazone	hydrochloride	and	its	process	
related	 impurities	 (impurity	 A,	 B	 and	 C)	 were	 weighed	
accurately	and	transferred	into	100	mL	volumetric	flask,	60	mL	
of	 diluent	 was	 added,	 sonicated	 for	 10	 min	 to	 dissolve	 the	
compounds	 and	 the	 volume	 was	 made	 up	 to	 100	 mL	 with	
diluent.	 5	 mL	 of	 this	 solution	 was	 made	 up	 to	 50	 mL	 with	
diluent	to	get	a	concentration	of	38	µg/mL.	This	impurity	stock	
solution	 was	 adequately	 diluted	 to	 study	 accuracy,	 precision,	
linearity,	robustness,	limit	of	detection	and	quantitation.	
	
2.3.7.	Chromatographic	conditions	
	
To	develop	a	suitable	and	robust	RP‐HPLC	method	for	 the	
determination	 of	 pioglitazone	 hydrochloride	 and	 its	 process	
related	 impurities,	 different	mobile	 phases	 and	 columns	were	
employed	 to	 achieve	 the	 best	 separation	 and	 resolution.	 The	
method	 development	 was	 initiated	 with	 C18	 column	 using	 a	
mobile	 phase	 containing	 water	 and	 acetonitrile	 as	 organic	
modifier.	Broad	peaks	were	observed	with	this	mobile	phase.	In	
the	 above	 mobile	 phase	 water	 was	 replaced	 with	 phosphate	
buffer.	 Peak	 symmetry	 was	 not	 good.	 To	 improve	 the	 peak	
shapes,	 ammonium	 acetate	 buffer	 was	 used	 in	 place	 of	
phosphate	 buffer.	 It	 gave	 sharp	 peaks	 but	 the	 problem	 is	
impurities	 are	 merging.	 Compounds	 are	 having	 varying	
polarities.	 A	 gradient	 elution	 mode	 was	 tried;	 many	
experiments	 were	 conducted	 by	 using	 different	 gradient	
programs	 and	 columns	 while	 optimizing	 the	 pH	 of	 buffer,	
buffer	 concentration,	 organic	 modifier	 strength	 and	
wavelength.	 Finally	 the	 best	 results	 were	 observed	 using	 a	
column	 C18	ODS	 (150	 ×	 4.6	mm),	mobile	 phase	 consisting	 of	
Solvent	 A:	 ammonium	 acetate	 buffer	 and	 acetonitrile	 in	 the	
ratio	(57:43,	v:v).		
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Table	1.	System	suitability	data.	
Name	 RT	 RRT Resolution	(Rs) Theoretical	plates	(N)	 Peak	symmetry	(As)
Impurity‐A	 3.478	 0.41 ‐ 2944.3 1.1	
Impurity‐B	 10.770	 1.28	 5.8	 13461	 1.0	
Impurity‐C	 18.000	 2.15	 25.1	 122171.6	 1.1	
Pioglitazone	hydrochloride	 8.436	 1.06	 14.1	 5622.5	 1.0	
	
	
Table	2.	Linearity	for	impurity‐A.	
Sample	no	 Concentration	(µg/mL)	 Peak	area Mean	peak	area	
1	 0.187	 6144	
6246	
6533	
6307.6	
2	 0.374	
	
12331
12381	
12152	
12288	
3	 0.748	 22932
23435	
23277	
23214.7	
4	 1.122	 37399	
37439	
37409	
37415.7	
5	 1.496	 49598	
49859	
50112	
49856.3	
6	 1.875	 64068
65395	
65055	
64839.3	
7	 2.244	 76150
76795	
76272	
76405.67	
Correlation	coefficient	 0.9986
Slope	 34558
Intercept	 ‐1078.9
	
	
Solvent	B:	ammonium	acetate	buffer	and	acetonitrile	in	the	
ratio	 (20:80,	 v:v)	 at	 a	 flow	 rate	 of	 1.0	 mL/min.	 According	 to	
gradient	elution	program	0‐7	min	(100%	A),	7‐20	min	(100%	
B),	 20‐21	 min	 (100%	 A).	 In	 the	 above	 chromatographic	
conditions	 gave	 sharp	 peaks	 with	 minimum	 tailing,	 good	
resolution	and	shorter	runtime	for	pioglitazone	hydrochloride	
and	its	process	related	impurities	(Figure	2).		
	
	
	
Figure	2.	Typical	chromatogram	for	LOQ.	
	
3.	Results	and	discussion		
	
Analytical	method	validation	is	a	process	that	demonstrates	
the	 suitability	 of	 the	 proposed	 procedures	 for	 the	 intended	
purpose.	 More	 specifically,	 it	 is	 a	 matter	 of	 establishing	
documented	 evidence	 providing	 a	 high	 degree	 of	 assurance	
with	 respect	 to	 the	 consistency	 of	 the	method	 and	 results	 to	
evaluate	 the	 product	 against	 defined	 specifications.	 The	
validation	 parameters	 viz.,	 specificity,	 accuracy,	 precision,	
linearity,	 limit	 of	 detection,	 limit	 of	 quantitation,	 robustness,	
system	 suitability	 have	 to	 be	 evaluated	 as	 per	 the	 ICH	
guidelines	for	all	analytical	methods	developed	by	HPLC.	
	
3.1.	System	suitability	
	
This	 is	 an	 integral	 part	 of	 development	 of	 a	
chromatographic	 method	 to	 verify	 that	 the	 resolution	 and	
reproducibility	 of	 the	 system	 are	 adequate	 enough	 for	 the	
analysis	 to	 be	 performed.	 It	 is	 based	 on	 the	 concept	 that	 the	
equipment,	 electronics,	 analytical	 operations	 and	 samples	
constituting	an	 integral	system	could	be	evaluated	as	a	whole.	
Parameters	 such	 as	 plate	 number	 (N),	 asymmetry	 or	 tailing	
factors	 (As),	 relative	 retention	 time	 (RRT),	 resolution	 (Rs)	 and	
reproducibility	 (%	 R.S.D),	 retention	 time	 were	 determined	
(Table	 1).	 These	 parameters	 were	 determined	 during	 the	
analysis	 of	 a	 "sample"	 containing	 the	 main	 components	 and	
related	 substances.	 System	 suitability	 parameters	 were	
determined	and	compared	with	the	recommended	limits	(1	≥	As	
≤	2	and	Rs	>	1.5).	
	
3.2.	Specificity	
	
Specificity	 is	 the	 ability	 of	 the	 method	 to	 measure	 the	
analyte	response	 in	presence	of	 its	process	related	 impurities.	
The	specificity	of	 the	developed	HPLC	method	was	performed	
by	 injecting	 blank	 solution	 and	 standard	 solution	 spiked	with	
process‐related	 impurities	 separately.	 The	 chromatogram	 of	
drug	 with	 impurities	 was	 compared	 with	 the	 blank	
chromatogram,	 to	 verify	 the	 blank	 interference.	 No	 peak	was	
observed	 at	 the	 retention	 time	 of	 pioglitazone	 hydrochloride	
and	 its	 impurities.	 Hence	 the	 method	 is	 specific	 for	 the	
determination	 of	 process	 related	 impurities	 in	 pioglitazone	
hydrochloride.	
	
3.3.	Linearity	
	
Standard	solutions	at	different	concentration	levels	ranging	
from	 LOQ	 to	 2.25	 μg/mL	 (150%	 of	 specification	 limit)	 were	
prepared	 and	 analyzed	 in	 triplicate.	 In	 order	 to	 demonstrate	
the	 linearity	 of	 detector	 response	 for	 pioglitazone	
hydrochloride	and	 its	 impurities,	 the	 linearity	plot	was	drawn	
taking	the	concentration	on	X	axis	and	the	mean	peak	area	on	Y	
axis.	 The	 data	 was	 subjected	 to	 statistical	 analysis	 using	 a	
linear‐regression	 model	 the	 regression	 equations	 and	
correlation	coefficients	(r2)	are	given	in	Tables	2‐5.	
	
3.3.1.	Acceptance	criteria	
	
The	correlation	coefficient	should	not	be	less	than	0.99.	
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Table	3.	Linearity	for	impurity‐B.	
Sample	no	 Concentration	(µg/mL)	 Peak	area Mean	peak	area	
1	 0.376	 8213	
8279	
8201	
8231	
2	 0.751	 15503	
15834	
15743	
15693.3	
3	 1.127	 24698
24657	
24651	
24668.7	
4	 1.502	 32541
32596	
32775	
32637.3	
5	 1.878	 42168	
42836	
42619	
42541.0	
6	 2.253	 50172
50211	
50056	
50146.3	
Correlation	coefficient	 0.9988	
Slope	 22684
Intercept	 ‐831.97
	
	
Table	4.	Linearity	for	impurity	C.	
Sample	no	 Concentration	(µg/mL)	 Peak	area Mean	peak	area	
1	 0.377	 5964	
5980	
5611	
5851.67	
2	 0.754	 10844
10983	
11143	
10990	
3	 1.131	 17778
17680	
17812
17756.7	
4	 1.508	 23417	
23398	
23630	
23481.7	
5	 1.885	 29919
30352	
30205	
30158.7	
6	 2.262	 35392
35575	
35455
35474	
Correlation	coefficient	 0.9988
Slope	 16017
Intercept	 ‐515.48
	
	
Table	5.	Linearity	for	pioglitazone	hydrochloride.	
Sample	no	 Concentration	(µg/mL)	 Peak	area	 Mean	peak	area	
1	 0.376	 4351
3505	
3965	
3940.3	
2	 0.751	 7298
7904	
8666	
7956	
3	 1.127	 13099	
12461	
12883	
12814.3	
4	 1.502	 17290
16485	
16587	
16787.3	
5	 1.878	 21674
24821	
22442	
22979	
6	 2.253	 27411	
28640	
27112	
27721	
Correlation	coefficient	 0.9959
Slope	 12780
Intercept	 ‐1433.5	
	
	
3.4.	Accuracy	and	recovery	
	
Accuracy	of	 the	 test	method	was	determined	by	analysing	
pioglitazone	 hydrochloride	 drug	 substance	 spiked	 with	
impurities	 at	 three	 different	 concentration	 levels	 of	 50%,	
100%,	and	150%	of	each	in	triplicate	at	the	specified	limit.	The	
mean	recoveries	of	all	the	impurities	were	calculated	(Table	6).	
The	%	recovery	obtained	 is	well	within	 the	 limit	of	85‐115%.	
This	 indicated	 that	 the	 method	 is	 accurate	 to	 determine	 the	
process	impurities	in	pioglitazone	hydrochloride.	
	
3.4.1.	Acceptance	criteria	
	
The	mean	percent	recovery	of	 the	 impurities	at	each	 level	
should	be	not	less	than	85.0%	and	not	more	than	115.0%.	
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Table	6.	Recovery	studies	for	impurities	of	pioglitazone	hydrochloride.	
Name	 Spike	Level	(%)	 Concentration	spiked	(μg/mL)	 Concentration	recovered	(μg/mL)	 %	Recovery	a	
Impurity‐A	 50	 0.76	 0.83 109.2
100	 1.52	 1.64 107.9
150	 2.28	 2.49 109.2
Impurity‐B	 50	 0.75	 0.72 96.0
100	 1.50	 1.42 94.7
150	 2.25	 2.13 94.7
Impurity‐C	 50	 0.78	 0.88	 112.8	
100	 1.56	 1.68	 107.7	
150	 2.34	 2.50 106.8
a	Average	of	three	determinations.	
	
	
Table	7.	Precision	studies	for	pioglitazone	hydrochloride	and	its	impurities.	
Name	 Method	precision	%R.S.D	(n=6) Intermediate	precision
Intraday	%RSD	(n=6) Interday	%RSD	(n=6)
Impurity‐A	 0.58	 0.53±0.09 0.51±0.06	
Impurity‐B	 0.61	 0.63±0.05 0.65±0.09	
Impurity‐C	 0.88	 0.86±0.07 0.91±0.09	
Pioglitazone	hydrochloride	 0.36	 0.39±0.09 0.42±0.07	
	
	
Table	8.	Results	for	limit	of	quantitation.	
S.	No	 Name		 Concentration	(µg/mL)	 Observed	signal	to	noise	ratio	
1	 Impurity‐A	 0.187 9.9
2	 Impurity‐B	 0.376 10.2
3	 Impurity‐C	 0.377 10.4
4	 Pioglitazone	hydrochloride	 0.751	 9.8	
		
	
Table	9.	Results	for	limit	of	detection.	
S.	No	 Name		 Concentration	(µg/mL) Observed	signal	to	noise	ratio	
1	 Impurity‐A	 0.061 2.9
2	 Impurity‐B	 0.124	 3.1	
3	 Impurity‐C	 0.124	 3.4	
4	 Pioglitazone	hydrochloride	 0.250	 2.8	
		
	
3.5.	Precision	
	
System	precision	of	the	method	was	evaluated	by	injecting	
the	 standard	 solution	 six	 times	 and	percent	 relative	 standard	
deviation	(%	R.S.D)	for	area	of	pioglitazone	hydrochloride	peak	
was	calculated.	 It	was	 found	 to	be	 less	 than	2.0%	(R.S.D).	The	
precision	 of	 the	 method	 for	 the	 determination	 of	 impurities	
related	 to	 pioglitazone	 hydrochloride	 was	 studied	 for	
repeatability	 and	 intermediate	 precision	 at	 100%	 level.	
Repeatability	 was	 demonstrated	 by	 analysing	 the	 standard	
solution	 spiked	with	 impurities	 for	 six	 times.	 The	%R.S.D	 for	
peak	 area	 of	 each	 impurity	 was	 calculated.	 Intermediate	
precision	 was	 demonstrated	 by	 analysing	 same	 sample	 of	
pioglitazone	 hydrochloride	 by	 two	 different	 analysts	 on	 two	
different	 days	 (Inter‐day).	 Intra‐day	 variations	 of	 impurities	
related	to	pioglitazone	hydrochloride	are	expressed	in	terms	of	
%	 R.S.D	 Values.	 Repeatability	 and	 intermediate	 precision	 for	
the	 process‐related	 impurities	 in	 Pioglitazone	 hydrochloride	
were	found	to	be	less	than	1.0%	R.S.D.	The	results	are	given	in	
Table	7,	which	confirmed	good	precision	of	the	method.	
	
3.6.	Limit	of	detection	(LOD)	and	limit	of	quantitation	(LOQ)	
	
The	 limit	 of	 detection	 (LOD)	 and	 limit	 of	 quantification	
(LOQ)	 represent	 the	 concentration	 of	 the	 analyte	 that	 would	
yield	 signal‐to‐noise	 ratios	 of	 3	 for	 LOD	 and	 10	 for	 LOQ,	
respectively.	LOD	and	LOQ	were	determined	by	measuring	the	
magnitude	 of	 analytical	 background	 by	 blank	 samples	 and	
calculating	 the	 signal‐to‐noise	 ratio	 for	 each	 compound	 by	
injecting	a	series	of	solutions	until	S/N	ratio	3	for	LOD	and	10	
for	LOQ.	LOQ	and	LOD	values	are	given	in	Table	8	and	9	and	its	
chromatograms	were	shown	in	Figures	2	and	3.	
	
3.7.	Robustness	
	
To	 determine	 the	 robustness	 of	 the	 developed	 method,	
chromatographic	 conditions	 were	 deliberately	 altered.	 The	
parameters	 selected	were	 change	 in	 flow	 rate	 (±0.2	mL/min),	
change	in	pH	of	the	buffer	(±0.2),	change	in	the	ratio	of	mobile	
phase	 (±	4%)	and	change	 in	 the	 column	 temperature	 (±5	 °C),	
the	rest	of	 the	chromatographic	conditions	 for	each	alteration	
study	 was	 kept	 constant.	 In	 all	 the	 deliberately	 varied	
chromatographic	 conditions,	 no	 significant	 change	 was	
observed,	 which	 confirmed	 the	 robustness	 of	 the	 developed	
method.	
	
	
	
Figure	3.	Typical	chromatogram	for	LOD.	
	
4.	Conclusion	
	
A	 new	 gradient	 RP‐HPLC	 method	 was	 developed	 for	 the	
separation	and	determination	of	process	 related	 impurities	 in	
pioglitazone	hydrochloride	and	validated	as	per	ICH	guidelines.	
The	 method	 was	 found	 to	 be	 simple,	 selective,	 precise,	
sensitive,	 robust	 and	 accurate.	 Therefore,	 this	method	 can	 be	
used	 for	 routine	 testing	 as	 well	 as	 stability	 analysis	 of	
pioglitazone	 hydrochloride	 drug	 substance.	 All	 statistical	
results	 (Mean,	 %RSD	 and	 %recovery)	 were	 within	 the	
acceptance	criteria.		
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